• EnglishEnglish
    • Deutsch Deutsch
    • Italiano Italiano
    • Français Français
    • 日本語 日本語
    • 한국어 한국어

CISEMA - China Zertifizierung, Einkauf und Qualitätssicherung

  • Services
    • NMPA Registration – Medical Devices and IVDs
    • NMPA Registration & DMF – Pharmaceuticals
    • NMPA Registration – Cosmetics
    • NMPA Registration – Health Food
    • CML (China Manufacture Licence) – Pressure vessels
    • CCC (China Compulsory Certification) – Industrial and consumer goods
    • Others
      • Sourcing and Quality Control
      • Logistics and Customs Support
      • Sales Support
  • About us
    • Partners
    • Company Profile
    • Testimonials
  • Locations
  • Events
    • Trade Fairs & Conferences
    • Seminars
    • Webinars
  • News & Knowledge
    • Regulatory News
      • Medical Devices and IVDs
      • Cosmetics
      • Pharmaceuticals & DMF
      • CCC
      • Pressure Vessels
    • Whitepapers
    • FAQ – NMPA Registration – Medical Devices and IVDs
    • Newsletter Sign Up
    • Others
      • Publications
      • Online Shop
Contact
  • Home
  • News
  • News
  • China Clinical Trials for Drugs GMP appendix has been released

China Clinical Trials for Drugs GMP appendix has been released

china clinical trials drugs GMP
Tuesday, 07 June 2022 / Published in News, NMPA Registration in China, Pharmaceuticals & DMF

China Clinical Trials for Drugs GMP appendix has been released

China clinical trials for drugs GMP have been strengthened. The NMPA has supplemented the Good Manufacturing Practice (GMP) for Pharmaceutical Products (revised in 2010) with an Appendix on “GMP for Drugs for Clinical Trial”.

The Appendix (No.43-2022) was published on May 27, 2022 and will be implemented on July 1, 2022. It is the 13th appendix to the GMP for Pharmaceutical Products (2010 revision).

This Appendix clarifies that the preparation and quality control of drugs for use in clinical trials should:

  • follow the basic principles and data reliability requirements of Good Manufacturing Practice
  • minimize the risk of contamination, cross-contamination, confusion, and errors in the preparation process
  • ensure the quality of drugs used in clinical trials and ensure the safety of subjects.

In the past, the management of drugs for use in clinical trials in China was relatively vague. The production of commercial products needs to meet GMP standards, clinical trial research needs to meet Good Clinical Practice (GCP), and non-clinical research (laboratory) needs to meet Good Laboratory Practices (GLP). However, the management of drugs for use in clinical trial drugs was not clear enough.

The appendix is applicable to the preparation of drugs for clinical trials including experimental drugs and placebos. The GMP is also applicable to marketed drugs used as control drugs or test drugs, including changes in packaging and labeling.

THE MAIN HIGHLIGHTS OF THE NEW GMP FOR CHINA CLINICAL TRIALS FOR DRUGS:

Responsible person for release of the clinical trial drug

  • The applicant shall nominate a responsible person for release of the clinical trial drug.
  • Before approving the release, the responsible person for release shall conduct a quality evaluation of each batch of drugs for the clinical trial to ensure that they meet the laws, regulations and technical requirements.
  • The quality evaluation of the drugs for the clinical trial shall have clear conclusions, such as approval for release, non-release or other decisions, and these conclusions shall be signed by the responsible person for release.
  • A record review of the release of drugs for clinical trials shall be issued.

Creation of a drug file for the clinical trial

  • The applicant shall establish a drug file for clinical trials, and continuously update it with the progress of drug research and development to ensure traceability.
  • The file shall be used as the basis for the assessment of the release of drugs for clinical trials. When drugs for clinical trials are prepared in different steps at different sites, the applicant shall summarize and save relevant documents such as stability data, storage and transportation conditions, batch production records, etc. of all the sites.
  • Thefiles of drugs used in clinical trials shall be kept for at least 2 years after the delisting of the drugs. If the drug is not approved for marketing, it shall be kept for 2 years after the end of the clinical trial or after the termination of the registration application.

Preparation of drugs for clinical trials

  • The preparation of drugs for clinical trials should be able to ensure the uniform quality of the same batch of products. When drugs for clinical trials are prepared at different sites, a study on the comparability of drug quality between different sites shall be carried out.

China Clinical Trials Regulations for Drugs

As a reminder here is a list of the main regulations that you need to be aware of when conducting clinical trials in China:

  • Good Clinical Practice of Drugs (No.57-2020)
  • Guidelines for the Management of Phase I Clinical Trials of Drugs (Trial) (No.483)

By Yu and Victoria. If you would like to learn more about Clinical Trial Drugs, Good Manufacturing Practice (GMP) or our registration and CRO services for pharmaceuticals, medical devices, IVDs, cosmetics, health foods, industrial or consumer goods contact Cisema.

GET IN TOUCH

🌐 Send us your enquiry
📚 Request our whitepapers
📣 Sign up for our newsletter

What you can read next

china gmp for sterile and implantable
China GMP Medical Device 2022 Edition for Sterile and Implantable Devices
Cisema Webinar with IHK Lübeck (Chamber of Commerce): China – Market potential and registration of medical devices and IVDs
NMPA Releases FAQ for Cosmetics Businesses in China – November 2021

Search

Categories

  • Fairs & Events
  • News
    • CCC
    • CEL
    • CML, SELO
    • Medical Devices Listing in Hong Kong
    • NMPA Registration in China
      • Cosmetics
      • Health Food
      • Medical Device
      • Pharmaceuticals & DMF
    • RoHS
    • Voluntary Product Certification
  • Publications
  • Seminars
  • Uncategorized
  • Webinars

Recent Posts

  • China medical device sampling inspection results

    China medical device sampling inspection results no.4 of 2022

    China medical device sampling inspection result...
  • NMPA cosmetic sampling inspection

    The NMPA Cosmetic Sampling Inspection measures come into force on March 1, 2023

    NMPA Cosmetic Sampling Inspection Measures come...
  • China cosmetics quality safety responsibilities

    China cosmetics quality and safety responsibilities regulations released

    China cosmetics quality and safety responsibili...
  • China cosmetics efficacy claims FAQ

    China cosmetics efficacy claims FAQ available to answer key questions

    China cosmetics efficacy claims FAQ is availabl...
  • China cosmetics GMP inspections

    China cosmetics GMP inspections points have been finalised

    China cosmetics GMP inspections points and judg...

Archive

Cisema

With twelve locations and over ninety highly qualified employees, Cisema can offer you optimal support in China.

Services

  • Certification
  • Sourcing and Quality Control
  • Logistics and Customs Support
  • Sales Support

Dialogue

  • Contact us
  • Newsletter Signup
  • Events
  • News & Knowledge
  • Partners

Company

  • GTC
  • Privacy Statement
  • Legal Notice
  • About us
  • Locations
  • GET SOCIAL

© 2021 Cisema. All rights reserved.

TOP
Cookies on Cisema
Learn more about Cisema's Privacy Policy.